Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 2.256
Filter
1.
Fisioter. Bras ; 22(6): 881-894, Fevereiro 7, 2022.
Article in English | LILACS | ID: biblio-1358377

ABSTRACT

Background: Adherence to treatment is critical when dealing with chronic diseases. One of the difficulties in maintain long-term adherence is the distance from home to rehabilitation center. Objective: To determine the influence of the distance from subjects' residence to rehabilitation center on adherence of a 12-week pulmonary rehabilitation program in chronic respiratory disease. Methods: This retrospective study analyzed patients' medical records with chronic respiratory diseases from a pulmonary rehabilitation center. Driving distance between patients' home and rehabilitation center was calculated with Google maps. The home-rehabilitation center distances were classified in three levels: up to 10, 10-30 and more than 30 km. Results: 280 medical records from patients with chronic pulmonary diseases with medical indication to follow the pulmonary rehabilitation program were found and 148 medical records were included in our study. Out of them, the majority (n = 93) had chronic obstructive pulmonary disease (COPD). Seventy percent of patients lived up to 10 km, 24% lived between 10 and 30 km and 6% lived more than 30 km. No difference in adherence was found comparing the three groups based on the distance from home to rehabilitation center. Conclusion: In this study, distance between home and rehabilitation center did not influence adherence to pulmonary rehabilitation program. (AU)


Subject(s)
Rehabilitation Centers , Therapeutics , Residence Characteristics , Medical Records , Pulmonary Disease, Chronic Obstructive
2.
Alerta (San Salvador) ; 5(1): 26-32, ene. 28, 2022. ilus, tab
Article in Spanish | LILACS, BISSAL | ID: biblio-1354409

ABSTRACT

El tabaquismo es considerado un factor desencadenante de las principales enfermedades no transmisibles (ENT), como enfermedades cardiovasculares, enfermedad pulmonar obstructiva crónica, cáncer de pulmón, diabetes mellitus, insuficiencia renal, entre otras; así también, el tabaquismo se considera la principal causa de muerte que se puede prevenir a nivel mundial. En un estudio llevado a cabo en El Salvador se mencionan las principales ENT con antecedente de tabaquismo en el 2016, entre las que se encontraron la enfermedad isquémica del corazón, la enfermedad pulmonar obstructiva crónica, infecciones respiratorias, cáncer de pulmón, diabetes mellitus (DM), enfermedad cardiovascular hemorrágica, enfermedad hipertensiva y otras enfermedades cardiovasculares5. En este sentido, existe evidencia de una posible relación del tabaquismo con principales diagnósticos de ENT en el país; sin embargo, es necesario actualizar la información científica y estimar esta relación, sobre todo en grupos de personas que asisten a consulta en los principales centros de salud del primer nivel de atención en el país


Smoking is considered a triggering factor for the main noncommunicable diseases (NCDs), such as cardiovascular diseases, chronic obstructive pulmonary disease, lung cancer, diabetes mellitus, kidney failure, among others; Likewise, smoking is considered the main cause of death that can be prevented worldwide. In a study carried out in El Salvador, the main NCDs with a history of smoking in 2016 are mentioned, among which are ischemic heart disease, chronic obstructive pulmonary disease, respiratory infections, lung cancer, diabetes mellitus (DM), hemorrhagic cardiovascular disease, hypertensive disease and other cardiovascular diseases5. In this sense, there is evidence of a possible relationship between smoking and the main diagnoses of NCDs in the country; however, it is necessary to update the scientific information and estimate this relationship, especially in groups of people who attend consultations in the main health centers of the first level of care in the country


Subject(s)
Tobacco Use Disorder , Smoking , Disease , Noncommunicable Diseases , Primary Health Care , Cardiovascular Diseases , Pulmonary Disease, Chronic Obstructive , Diabetes Mellitus
3.
Braz. j. biol ; 82: e231134, 2022. tab, graf
Article in English | LILACS | ID: biblio-1249257

ABSTRACT

Abstract Chronic obstructive pulmonary disease (COPD) was estimated to be the third cause of global mortality by 2020. Acute exacerbation COPD (AECOPD) is a sudden worsening of COPD symptoms and could be due to virus/bacterial infections and air pollution. Increased expression of inflammatory markers in patients with AECOPD is associated with viral infection. This study aimed to detect different viruses and analyze the expression of various inflammatory markers associated with AECOPD patients. Three hundred and forty-seven patients diagnosed with COPD according to GOLD criteria were included in this study. Swab samples and blood were collected for the detection of viruses by RT-PCR and expression of inflammatory markers, respectively. Of the swab samples, 113 (32.6%) of samples were positive for virus detection. Of these, HRV (39.8%) was the predominant virus detected followed by FluB (27.4%) and FluA (22.1%). The presence of HRV was significantly higher (p=0.044) among the other detected viruses. When compared to healthy controls the expression levels of TNF-α, IL-6 and IL-8 were significantly higher (p<0.05) in virus-positive patients. The IL-6 and IL-8 were the next predominantly expressed in markers among the samples. The higher expression rate of IL-8 was significantly (p<0.05) associated with patients having COPD GOLD III severity level and smoking history. Although HRV was the predominant virus detected the combined prevalence of Influenza A and B surpassing the rate of HRV. The high-level expression of well known inflammatory markers of AECOPD, TNF-α, IL-6 and IL-8 indicates a chronic severe illness. These markers play an important role and could be used as a marker for determining the severity of AECOPD.


Resumo Estima-se que a doença pulmonar obstrutiva crônica (DPOC) seja a terceira causa de mortalidade global em 2020. A exacerbação aguda DPOC (AECOPD) é um agravamento súbito dos sintomas da DPOC e pode ser devido a infecções por vírus/bactérias e poluição do ar. O aumento da expressão de marcadores inflamatórios em pacientes com AECOPD está associado à infecção viral. Este estudo teve como objetivo detectar diferentes vírus e analisar a expressão de vários marcadores inflamatórios associados a pacientes com AECOPD. Trezentos e quarenta e sete pacientes com diagnóstico de DPOC de acordo com os critérios GOLD foram incluídos neste estudo. Amostras de swab e sangue foram coletadas para detecção de vírus por RT-PCR e expressão de marcadores inflamatórios, respectivamente. Das amostras de esfregaço, 113 (32,6%) amostras foram positivas para detecção de vírus. Nestas, o HRV (39,8%) foi o vírus predominante detectado, seguido do FluB (27,4%) e do FluA (22,1%). A presença de VFC foi significativamente maior (p = 0,044) entre os demais vírus detectados. Quando comparados a controles saudáveis, os níveis de expressão de TNF-α, IL-6 e IL-8 foram significativamente maiores (p <0,05) em pacientes com vírus positivo. A IL-6 e a IL-8 foram as próximas predominantemente expressas em marcadores entre as amostras. A maior taxa de expressão de IL-8 foi significativamente (p <0,05) associada a pacientes com grau de gravidade GOLD III da DPOC e história de tabagismo. Embora o HRV tenha sido o vírus predominante, a prevalência combinada de Influenza A e B ultrapassou a taxa de HRV. O alto nível de expressão de marcadores inflamatórios bem conhecidos de AECOPD, TNF-α, IL-6 e IL-8 indica uma doença crônica grave. Esses marcadores desempenham um papel importante e podem ser usados como um marcador para determinar a gravidade da AECOPD.


Subject(s)
Humans , Viruses , Pulmonary Disease, Chronic Obstructive/diagnosis , China/epidemiology , Cytokines/genetics , Mongolia
5.
Article in English, Portuguese | LILACS, BDENF | ID: biblio-1361338

ABSTRACT

Objetivo: classificar os pacientes segundo o risco de desenvolvimento de mediastinite no pós-operatório de cirurgia de revascularização do miocárdio. Método: estudo observacional, transversal, realizado na Unidade de Terapia Intensiva Pós-Operatória de um hospital universitário no interior paulista. Amostra consecutiva e não probabilística foi constituída por pacientes adultos, submetidos à revascularização do miocárdio. A coleta de dados foi realizada na alta da Terapia Intensiva, utilizando o Escore de Risco Multivariável para Mediastinite. Para a obtenção do escore foram realizadas análises estatística descritivas. Resultados: participaram do estudo 50 pacientes, 68% do sexo masculino, com média de idade de 62,7 anos. Nenhum paciente foi reoperado ou apresentava doença pulmonar obstrutiva crônica; 26,0% eram obesos; 12,0% apresentaram angina instável e 4,0% foram politransfundidos no pós-operatório. Segundo o escore, 58,0% apresentaram baixo e 42,0% médio risco de desenvolvimento de mediastinite. Conclusão: a maior parte dos pacientes apresentava baixo risco de desenvolvimento de mediastinite


Objective: to classify patients according to the risk of developing mediastinitis in the postoperative period of myocardial revascularization surgery. Method: observational, cross-sectional study, carried out in the Post-Operative Intensive Care Unit of a university hospital in the interior of São Paulo. Consecutive and non-probabilistic sample consisted of adult patients who underwent myocardial revascularization. Data collection was performed at discharge from the Intensive Care, using the Multivariable Risk Score for Mediastinitis. To obtain the score, descriptive statistical analyzes were performed. Results: the50 patients participated in the study, 68% were male, with a mean age of 62.7 years. No patient was reoperated or had chronic obstructive pulmonary disease; 26.0% were obese; 12.0% had unstable angina and 4.0% were transfused in the postoperative period. According to the score, 58.0% had a low and 42.0% medium risk of developing mediastinitis. Conclusion: most patients were at low risk of developing mediastinitis


Objetivo: clasificar a los pacientes según el riesgo de desarrollar mediastinitis en el postoperatorio de cirugía de revascularización miocárdica. Método: estudio observacional, transversal, realizado en la Unidad de Cuidados Intensivos Posoperatorios de un hospital universitario del interior de São Paulo. La muestra consecutiva y no probabilística estuvo constituida por pacientes adultos sometidos a revascularización miocárdica. La recolección de datos se realizó al alta de la Unidad de Cuidados Intensivos, utilizando el Multivariable Risk Score para Mediastinitis. Para obtener la puntuación se realizaron análisis estadísticos descriptivos. Resultados: participaron en el estudio 50 pacientes, el 68% eran varones, con una edad media de 62,7 años. Ningún paciente fue reintervenido ni presentó enfermedad pulmonar obstructiva crónica; El 26,0% eran obesos; El 12,0% presentó angina inestable y el 4,0% recibió transfusión en el postoperatorio. Según el puntaje, el 58.0% tenía un riesgo bajo y el 42.0% medio de desarrollar mediastinitis. Conclusión: la mayoría de los pacientes tenían un riesgo bajo de desarrollar mediastinitis


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Risk Factors , Mediastinitis , Myocardial Revascularization , Postoperative Period , Perioperative Nursing , Critical Care , Pulmonary Disease, Chronic Obstructive , Angina, Unstable
6.
Article in Portuguese | ColecionaSUS, LILACS, ColecionaSUS, CONASS, SES-GO | ID: biblio-1359159

ABSTRACT

Tecnologia: Tripla terapia broncodilatadora (vilanterol/ umeclidínio/ fluticasona, formoterol/ glicopirrônio/ beclometasona) e dupla terapia. Indicação: Tratamento de doença pulmonar obstrutiva crônica (DPOC), formas grave e muito grave. Pergunta: Há diferenças de efeito nos principais desfechos de eficácia e segurança entre a tripla terapia broncodilatadora e as duplas terapias no tratamento de pacientes com DPOC, formas grave e muito grave? Métodos: Revisão rápida de evidências (overview) de revisões sistemáticas, com levantamento bibliográfico realizado na base de dados PUBMED, utilizando estratégia estruturada de busca. A qualidade metodológica das revisões sistemáticas foi avaliada com AMSTAR-2 (Assessing the Methodological Quality of Systematic Reviews). Resultados: Foram selecionadas e incluídas 2 revisões sistemáticas. Conclusão: A tripla terapia broncodilatadora era mais eficaz que a dupla terapia para reduzir a taxa anual de exacerbações moderadas a severas, mas não tinha superioridade para obter ganhos clínicos em outros desfechos (volume expiratório forçado no primeiro segundo, qualidade de vida, índice de dispneia, mortalidade geral, mortalidade respiratória), exceto que a tripla terapia era superior à dupla terapia com agonistas beta-2/ antagonistas antimuscarínicos e similar à dupla terapia com agonistas beta-2/ corticoesteróides inalatórios para reduzir mortalidade. A tripla terapia tinha perfil de segurança similar à dupla terapia, com mesmo risco para eventos adversos e eventos adversos graves. A tripla terapia tinha maior risco para pneumonias que a dupla terapia com agonistas beta-2/ antagonistas antimuscarínicos


Technology: Triple bronchodilator therapy (vilanterol/ umeclidinium/ fluticasone, formoterol/ glycopyrronium/ beclomethasone) and dual therapy. Indication: Treatment of chronic obstructive pulmonary disease (COPD), severe and very severe forms. Question: Are there differences in effects of efficacy and safety outcomes between triple bronchodilator therapy and dual therapies in treating patients with severe and very severe forms of COPD? Methods: Rapid review of evidence (overview) from systematic reviews, with a bibliographic search in the PUBMED database, using a structured strategy. The methodological quality of systematic reviews was assessed with AMSTAR-2 (Methodological Quality Assessment of Systematic Reviews). Results: Two systematic reviews were selected and included. Conclusion: Triple bronchodilator therapy was more effective than dual therapy in reducing the annual rate of moderate to severe exacerbations, but had no superiority for clinical gains in other outcomes (forced expiratory volume in first second, quality of life, dyspnea index, general mortality, respiratory mortality), except that, for reducing mortality, triple therapy was superior to dual therapy with beta-2 agonists/ antimuscarinic antimuscarinics and similar to dual therapy with beta 2 agonists/ inhaled corticosteroids. The triple therapy had a similar safety profile to dual therapy, with the same risk for adverse events and serious adverse events. The triple therapy had a higher risk for pneumonia than a dual therapy with beta-2 agonists/ antimuscarinic antagonists


Subject(s)
Humans , Bronchodilator Agents/therapeutic use , Pulmonary Disease, Chronic Obstructive/drug therapy , Beclomethasone/therapeutic use , Evidence-Based Medicine , Formoterol Fumarate/therapeutic use , Fluticasone/therapeutic use , Glycopyrrolate/therapeutic use
7.
Medicina (B.Aires) ; 81(supl.2): 1-32, dic. 2021. graf
Article in Spanish | LILACS | ID: biblio-1351083

ABSTRACT

Resumen En las últimas décadas ha habido un importante desarrollo de dispositivos inhalados (DI) que permiten aumentar la eficacia de las drogas y disminuir los eventos adversos. Su correcto uso es de fundamental importancia para el control de las enfermedades respiratorias obstructivas. En la Argentina no existen recomendaciones locales sobre el uso de los DI. Se revisó la base biofísica, indicación, ventajas y limitaciones, técnica de correcto uso, errores frecuentes, mantenimiento y limpieza de cada DI. El uso de nebulizaciones ha quedado restringido a la administración de drogas que no están disponibles en otros DI (ejemplo: tratamiento de fibrosis quística), o ante la falla de los otros DI. No deben ser usados durante la pandemia de SARS-CoV2. Los inhaladores de dosis medida (aerosol) deben ser indicados siempre con aerocámaras (AC), las que reducen la incidencia de eventos adversos y aumentan el depósito de la droga en el pulmón. Son los dispositivos de elección junto a los inhaladores de polvo seco. Los aerosoles se deben usar en pacientes que no generan flujos inspiratorios altos. Los inhaladores de polvo seco deben recomendarse en aquellos que pueden realizar flujos inspiratorios enérgicos. Se revisaron los diferentes DI en fibrosis quística y en pacientes con asistencia respiratoria mecánica. La elección del DI dependerá de varios factores: situación clínica, edad, experiencia previa, preferencia del paciente, disponibilidad de la droga y entrenamiento alcanzado con el correcto uso.


Abstract Last decades, a broad spectrum of inhaled devices (ID) had been developed to enhance efficacy and reduce adverse events. The correct use of IDs is a critical issue for controlling obstructive respiratory diseases. There is no recommendation on inhalation therapy in Argentina. This document aims to issue local recommendations about the prescription of IDs. Each device was reviewed regarding biophysical laws, indication, strength, limitations, correct technique of use, frequent mistakes, and device cleaning and maintenance. Nebulization should be restricted to drugs that are not available in other IDs (for example, for treatment of cystic fibrosis) or where other devices fail. Nebulization is not recommended during the SARS-CoV2 pandemic. A metered-dose inhaler must always be used with an aerochamber. Aerochambers reduce the incidence of adverse events and improve lung deposition. Metered-dose inhalers must be prescribed to patients who cannot generate a high inspiratory flow and dry powders to those who can generate an energetic inspiratory flow. We reviewed the use of different IDs in patients with cystic fibrosis and under mechanical ventilation. The individual choice of an ID will be based on several variables like clinical status, age, previous experience, patient preference, drug availability, and correct use of the device.


Subject(s)
Humans , Asthma , COVID-19 , Argentina , RNA, Viral , Pulmonary Disease, Chronic Obstructive , SARS-CoV-2
8.
Rev. cuba. med. mil ; 50(3): e1414, 2021. tab
Article in Spanish | LILACS, CUMED | ID: biblio-1357300

ABSTRACT

Introducción: El neumotórax espontáneo es la causa más frecuente de ingreso urgente en los servicios de cirugía torácica. Objetivo: Caracterizar a pacientes ingresados con diagnóstico de neumotórax espontáneo. Métodos: Se realizó un estudio descriptivo de 93 pacientes con diagnóstico clínico y radiológico de neumotórax espontáneo, se establecieron las variables del estudio y se utilizaron frecuencias absolutas y porcentajes. Para la asociación de las variables se empleó el estadígrafo ji cuadrado con un nivel de confiabilidad del 95 por ciento. Resultados: Predominó el neumotórax espontáneo primario (65,5 por ciento), el sexo masculino fue el más afectado (80,6 por ciento), con mayor frecuencia en el hemitórax derecho (72,2 por ciento) y el tabaquismo como antecedente (83,9 por ciento). La pleurostomía mínima fue el tratamiento definitivo en el 72 por ciento de los pacientes. La complicación más frecuente después de la pleurostomía, fue la fuga persistente de aire. El tratamiento quirúrgico con pleurodesis mecánica, ofreció un 100 por ciento de efectividad. La mortalidad quirúrgica fue nula. Conclusiones: El neumotórax espontáneo predomina en el sexo masculino en una proporción de 4,2:1, en pacientes menores de 40 años de edad. El antecedente patológico personal que más se asocia es la enfermedad pulmonar obstructiva crónica. El síntoma predominante es el dolor torácico. El neumotórax espontáneo primario fue más frecuente y el hemitórax derecho el más afectado. El tabaquismo está presente como antecedente en ambos tipos de neumotórax espontáneo. La modalidad de tratamiento más utilizada es la pleurostomía mínima(AU)


Introduction: Spontaneous pneumothorax is the most frequent cause of urgent admission to thoracic surgery services. Objective: To characterize patients admitted with a diagnosis of spontaneous pneumothorax. Methods: A descriptive study of 93 patients with a clinical and radiological diagnosis of spontaneous pneumothorax was carried out, the study variables were established and absolute frequencies and percentages were used. For the association of the variables, the chi square statistic was used with a confidence level of 95 percent. Results: Primary spontaneous pneumothorax predominated (65.5 percent), the male sex was the most affected (80.6 percent), with greater frequency in the right hemithorax (72.2 percent) and smoking as the antecedent (83.9 percent). Minimal pleurostomy was the definitive treatment in 72 percent of the patients. The most frequent complication after pleurostomy was persistent air leak. Surgical treatment with mechanical pleurodesis offered 100 percent effectiveness. There was not surgical mortality. Conclusions: Spontaneous pneumothorax predominated in males in a ratio of 4.2: 1, in patients under 40 years of age. The most associated personal pathological history was chronic obstructive pulmonary disease. The predominant symptom was chest pain. Primary spontaneous pneumothorax was more frequent and the right hemithorax the most affected. Smoking was present as a history in both types of spontaneous pneumothorax. The most widely used treatment modality was minimal pleurostomy(AU)


Subject(s)
Humans , Adolescent , Adult , Pneumothorax/diagnosis , Tobacco Use Disorder , Smoking , Clinical Diagnosis , Pleurodesis/methods , Pulmonary Disease, Chronic Obstructive , Pneumothorax/therapy , Pneumothorax/diagnostic imaging , Epidemiology, Descriptive , Thoracentesis/methods
9.
Rev. cuba. med. mil ; 50(3): e1284, 2021. tab
Article in Spanish | LILACS, CUMED | ID: biblio-1357315

ABSTRACT

Introducción: El síndrome respiratorio agudo grave (por la COVID-19) es en la actualidad la primera causa de muerte en el Perú, por lo que se requiere de fármacos eficaces y seguros para mitigar la enfermedad. Se realizó una búsqueda bibliográfica en SciELO y PubMed/ Medline; se seleccionaron 37 de 58 artículos sobre el tema. Objetivos: Revisar e integrar la información sobre las interacciones farmacocinéticas de la azitromicina que se prescriben en el tratamiento ambulatorio de la COVID-19 en el Perú, y evaluar su implicación clínica. Desarrollo: La azitromicina es usada en la COVID-19, por su actividad antiinflamatoria, al inhibir a las interleucinas (IL1, 6, 8 y TNF-α), y a las moléculas de adhesión intracelular 1 (ICAM1); y por inducir la producción de interferón tipo I (IFN-α, IFN-β) y III (IFN-λ) en células de pacientes con enfermedad pulmonar obstructiva crónica. Los estudios de tres brazos, aleatorizado y abierto, indican que la azitromicina no genera cambios en los parámetros farmacocinéticos de la ivermectina, sildenafilo, rupatadina y desloratadina; los estudios de un solo centro, abierto, sin ayuno y de dos períodos, evidencian que la azitromicina influye en los parámetros farmacocinéticos de venetoclax y de los psicotrópicos. Conclusiones: Basado en la evidencia de los estudios clínicos revisados e integrados, se concluye que estas son limitadas y de poca relevancia clínica, sin embargo, se propone usar el antibiótico bajo el criterio científico del médico, para evitar las interacciones farmacocinéticas y las reacciones adversas de los fármacos(AU)


Introduction: The severe acute respiratory syndrome (due to COVID-19) is currently the leading cause of death in Peru, so effective and safe drugs are required to mitigate the disease. A bibliographic search was carried out in SciELO and PubMed/Medline; 37 of 58 articles on the topic were selected. Objectives: Review and integrate the information on the pharmacokinetic interactions of azithromycin that are prescribed in the outpatient treatment of COVID-19 in Peru, and evaluate their clinical implication. Development: Azithromycin is used in COVID-19, due to its anti-inflammatory activity, by inhibiting interleukins (IL1, 6, 8 and TNF-α), and intracellular adhesion molecules 1 (ICAM1); and by inducing the production of type I interferon (IFN-α, IFN-β) and III (IFN-λ) in cells of patients with chronic obstructive pulmonary disease. The three-arm, randomized and open-label studies indicate that azithromycin does not cause changes in the pharmacokinetic parameters of ivermectin, sildenafil, rupatadine, and desloratadine; single-center, open-label, non-fasting, and two-period studies show that azithromycin influences the pharmacokinetic parameters of venetoclax and psychotropics. Conclusions: Based on the evidence from the reviewed and integrated clinical studies, it is concluded that these are limited and of little clinical relevance, however, it is proposed to use the antibiotic under the scientific criteria of the doctor, to avoid pharmacokinetic interactions and adverse reactions of drugs(AU)


Subject(s)
Humans , Azithromycin/therapeutic use , Pulmonary Disease, Chronic Obstructive/complications , Severe Acute Respiratory Syndrome/prevention & control , COVID-19/drug therapy , Anti-Bacterial Agents , Cause of Death
10.
Rev. cienc. salud ; 19(2): 1-16, mayo-ago. 2021. tab, graf, ilus
Article in Spanish | LILACS | ID: biblio-1347307

ABSTRACT

Resumen Introducción: la enfermedad pulmonar obstructiva crónica es progresiva, afecta la condición física y la calidad de vida. La educación de los pacientes que la padecen ha mostrado resultados positivos, al mejorar la adherencia al tratamiento, al favorecer el automanejo y al disminuir el número de exacer baciones, al igual que los costos de hospitalización. El objetivo de este estudio fue establecer el efecto de un programa de educación intrahospitalaria para pacientes con enfermedad pulmonar obstructiva crónica, en cuanto al grado de conocimiento de esta. Materiales y métodos: estudio cuasiexperimental con mediciones antes y después. Se utilizó el Cuestionario de Necesidad de Información Pulmonar (LINQ) para medir el conocimiento de la enfermedad antes del programa educativo y después de este, desarro llado en tres sesiones durante la hospitalización. Tres meses después, se indagó sobre la utilización de servicios de salud y la percepción del estado de salud. Resultados: participaron un total de 33 pacientes -19 mujeres (58 %) y 14 hombres (42 %)-, cuya edad promedio fue de 73.7 (±7.6); el 52 % con educación básica y el 88.8 % con un nivel socioeconómico bajo. En LiNQ-pre, el promedio fue de 14.55 (±4.25), y en el LINQ posintervención educativa, de 4.94 (±1.7). El puntaje total del Cuestionario Respiratorio Saint George fue 77.7, con mayor compromiso del dominio de limitación de la actividad, en 86.37. En el seguimiento a los tres meses, 19 pacientes (79 %) refirieron sentirse bien. Conclusión: a través de la intervención educativa, los pacientes mejoraron de manera estadísticamente significativa su conocimiento sobre la enfermedad. Un programa de educación intrahospitalario beneficia la atención del paciente y optimiza los recursos en salud.


Abstract Introduction: Chronic obstructive pulmonary disease is a progressive disease that compromises the physical condition and quality of life. Education has resulted in a positive outcome in terms of improving the adherence to treatment, encouraging self-management, and reducing the number of exacerbations as well as the hospitalization expenditure. The aim of the present study was to establish the effect of a hospital-based education program for patients with chronic obstructive pulmonary disease based on the level of knowledge of the disease. Materials and Methods: We performed a quasi-experimental before and after study. The Lung Information Need Questionnaire (LINQ) was employed to measure the level of knowledge of the disease, before and after the educational program was developed, in three sessions during the hospitalization. After three months, we investigated the use of health services and the per ception of the health status. Results: A total of 33 patients participated, which included 19 women (58%), 14 men (42%). The average age was 73.7 ± 7.6 years; 52% of participants had basic education; and 88.8% belonged to the low socioeconomic level. In LiNQ-pre, the average score was 14.55 ± 4.25, whereas LINQ post educational intervention average was 4.94 ± 1.7. The total score of the Saint George's Respiratory Questionnaire was 77.7 with a greater commitment of the activity limitation domain at 86.37. At three months follow-up, 19 patients (79%) reported improvement in health. Conclusions: Through educational intervention, patients significantly improved their knowledge of the disease. Therefore, it can be con cluded that a hospital-based education program benefits patient care and optimizes the health resources.


Resumo Introdução: a doença pulmonar obstrutiva crônica é uma doença progressiva que compromete a condi ção física e a qualidade de vida. A educação tem mostrado resultados positivos na melhoria da adesão ao tratamento, favorecer o autocuidado e reduzir o número de exacerbações e os custos de hospitalização. O objetivo deste estudo foi estabelecer o efeito de um programa de educação intra-hospitalar para pacientes com doença pulmonar obstrutiva crônica, no nível de conhecimento da doença. Materiais e métodos: estudo quase experimental com avaliações prévias e posteriores ao programa. O questionário de necessidade de informação pulmonar (LINQ) foi utilizado para mensurar o nível de conhecimento da doença antes e depois do programa educativo, desenvolvido em três sessões no decorrer da hospitalização. Três meses depois, questionou-se sobre a utilização de serviços de saúde e a percepção do estado de saúde. Resultados: parti ciparam 33 pacientes: sendo 19 mulheres (58%), 14 homens (42%), com média de idade de 73,7 (±7,6); 52% com ensino fundamental e 88,8% com baixo nível socioeconômico. No LiNQ-pré a média foi de 14,55 (±4,25), no LINQ pós-intervenção educacional a média foi de 4,94 (±1,7). O escore total do Questionário Respiratório do Hospital Saint George foi de 77,7 com um maior comprometimento do domínio de limitação de ativi dades em 86,37. Após os três meses, 19 pacientes (79%) relataram sentir-se bem. Conclusão: por meio de intervenção educativa, os pacientes aprimoraram seus conhecimentos sobre a doença de forma estatisti camente significativa. Um programa de educação intra-hospitalar beneficia o atendimento ao paciente e otimiza os recursos de saúde.


Subject(s)
Humans , Lung Diseases , Quality of Life , Health Education , Pulmonary Disease, Chronic Obstructive , Self-Management
11.
Rev. Pesqui. Fisioter ; 11(3): 536-543, ago.2021. ilus, tab
Article in English, Portuguese | LILACS | ID: biblio-1292382

ABSTRACT

| INTRODUÇÃO: O Timed UP and Go Test (TUG) é um importante teste utilizado para a avaliação de desfechos funcionais na DPOC, como mobilidade, equilíbrio dinâmico e risco de queda. No cenário clínico prático, a aplicação repetida do TUG é realizada muitas vezes pelo mesmo observador, no objetivo de avaliar diversas intervenções aplicadas na DPOC. OBJETIVO: Avaliar o grau de reprodutibilidade intraobservador do TUG em indivíduos com DPOC. METODOLOGIA: Estudo descritivo, de corte transversal, realizado com indivíduos com DPOC, atendidos ambulatorialmente na cidade de Salvador-Bahia. Foram verificadas características sociodemográficas e clínicas como a espirometria (VEF1/CVF), e tempo de realização de duas práticas no mesmo dia do teste TUG. A reprodutibilidade do TUG foi avaliada pelo Coeficiente de Correlação Intraclasse (CCI), CAAE número 38143214.0.0000.0057. RESULTADOS: Trinta e um pacientes voluntários foram avaliados; destes, 24 (77,4%) homens, média da idade de 68,6 ± 9,8 anos, com relação VEF1/CVF pós-broncodilatador de 59,0 ± 10,8 %. Na análise da reprodutibilidade intraobservador do TUG pelo CCI, obteve-se α = 0,897 (CI 95%: 0,786; 0,950; p < 0,0001). CONCLUSÃO: O teste TUG possui excelente reprodutibilidade intraobservador e uma pequena variabilidade quando aplicados duas vezes em pacientes com DPOC, sendo a aplicação para avaliação da mobilidade, na prática do cuidado em saúde considerada factível.


INTRODUCTION: The Timed UP and Go Test (TUG) is an important test used to assess functional outcomes in COPD, such as mobility, dynamic balance, and risk of falling. In clinical practice, the repeated application of the TUG is performed several times by the same observer to evaluate different interventions applied in COPD. OBJECTIVE: To assess the degree of intraobserver reproducibility of TUG in individuals with COPD. METHODOLOGY: Descriptive, cross-sectional study carried out with individuals with COPD treated in an outpatient clinic in the city of SalvadorBahia. Sociodemographic and clinical characteristics such as spirometry (FEV1/FVC) were verified, as well as two practices of the TUG Test on the same day. The reproducibility of TUG was evaluated fur Intraclass Correlation Coefficient (ICC). CAAE number 38143214.0.0000.0057. RESULTS: Thirty-one volunteer patients were evaluated, of which 24 (77.4%) men, mean age 68.6 ± 9.8 years, with post-bronchodilator FEV1//FVC ratio 59.0 ± 10.8%. In the analysis of intraobserver reproducibility of the TUG by the ICC, α = 0.897 (CI 95%: 0.786; 0.950; p < 0.0001) was obtained. CONCLUSION: The TUG test has excellent intraobserver reproducibility and a small variability when applied twice in patients with COPD, being the application for mobility assessment, in care practice, considered viable.


Subject(s)
Pulmonary Disease, Chronic Obstructive , Physical Therapy Modalities , Ambulatory Care
12.
Medicina (B.Aires) ; 81(3): 323-328, jun. 2021. graf
Article in Spanish | LILACS | ID: biblio-1346466

ABSTRACT

Resumen La presencia de sarcopenia (pérdida de masa y función muscular) implica peor pronóstico. Sin embargo, su diagnóstico es complejo y no se realiza en la atención clínica habitual. Se ha propuesto un biomarcador como estimador subrogado de la masa muscular esquelética, el denominado índice de sarcopenia ([creatinina sérica/cistatina C] x100) que se asocia a características pronósticas en diversas enfermedades incluyendo pacientes con enfermedad pulmonar obstructiva crónica (EPOC) estable. El objetivo de nuestro estudio ha sido evaluar de forma prospectiva la potencial información clínica y pronóstica de este biomarcador en agudización de la EPOC. Se trata de un estudio prospectivo, durante un año, de los pacientes consecutivos que ingresan por agudización de su EPOC. Se incluyeron 89 pacientes, 70 varones (79%) y 19 mujeres (21%). Aquellos con valores disminuidos del índice de sarcopenia tenían más disnea y requerían una internación más prolongada. En el análisis de correlación se obtuvo valores con significación estadística del índice con FEV1 (r = 0.23), PaCO (r = -0.30) y bicarbonato (r = -0.31), y con la disnea (r = -0.25) y la duración del ingreso (r =0.30). En los ingresados por agudización de la EPOC el índice de sarcopenia se relacionó con características pronósticas, de modo que los valores inferiores se asociaron a mayor duración de la internación, más disnea y mayor afectación funcional. Al tratarse de un índice asociado a la masa muscular, su determinación podría identificar a pacientes a incluir en un plan terapéutico diferenciado.


Abstract Sarcopenia (loss of muscle mass and function) implies a worse prognosis. However, its diagnosis is complex and is not made in routine clinical care. A biomarker has been proposed as a surrogate estimator of skeletal muscle mass, the so-called sarcopenia index ([serum creatinine/cystatine C] x100) which is associated with prognostic features in various diseases including patients with stable chronic obstructive pulmonary disease (COPD). The aim of our study was to prospectively evaluate the potential clinical and prognostic information of this biomarker in COPD exacerbation. This is a one-year prospective study of consecutive patients admitted for COPD exacerbation. A total of 89 patients, 70 men (79%) and 19 women (21%) were included. Those with lower values of the sarcopenia index had a higher level of dyspnoea and a longer hospitalization. In the correlation analysis, the index had statistically significant values with FEV1 (r = 0.23), PaCO (r = -0.30), bicarbonate (r = -0.31), dyspnoea (r = -0.25) and length of admission (r = -0.30). In patients admitted for COPD exacerbation, the sarcopenia index was related to prognostic characteristics, so that lower values were associated with longer duration of hospital admission, more dyspnoea and greater functional impairment. As this is an index associated with muscle mass, its determination may identify patients who could be the subject of a differentiated therapeutic plan.


Subject(s)
Humans , Male , Female , Pulmonary Disease, Chronic Obstructive/complications , Pulmonary Disease, Chronic Obstructive/diagnosis , Sarcopenia/diagnosis , Prognosis , Prospective Studies , Disease Progression , Hospitalization
13.
Cambios rev. méd ; 20(1): 107-116, 30 junio 2021. 107^c116
Article in Spanish | LILACS | ID: biblio-1292982

ABSTRACT

La neumonía es una infección frecuente que se presenta en todas las edades, en cualquier tipo de pacientes y a nivel co-munitario u hospitalario. La neumonía que se origina en la comunidad afecta a los pacientes con comorbilidades y en los extremos de la vida. La mortalidad de la neumonía comunitaria (NC) per-manece elevada, los sistemas de salud deben implementar estrategias para diagnosticar y tratar de forma rápida a estos pacientes. Cuando un paciente con neumonía comunitaria es ingresado en la emergencia de cualquier hospital se debe categorizar su estado para que reciba el mejor tratamiento posible. La Unidad de Cuidados Intensivos (UCI) participa en la detección de los pacientes con neu-monía adquirida en la comunidad grave, con el objetivo de priorizar su atención para lograr las metas de manejo lo más rápido posible y disminuir la mortalidad de estos pacientes.


Pneumonia is a common infection that occurs in all ages, in any type of patient and at the community or hospital level. Community-originating pneumonia affects patients with comorbidities and at the ex-tremes of life. Mortality from commu-nity pneumonia remains high, health sys-tems must implement strategies to quickly diagnose and treat these patients. When a patient with community pneumonia is admitted to any hospital emergency, their condition must be categorized so that they receive the best possible treat-ment. The Intensive Care Unit (ICU) participates in the detection of patients with severe community-acquired pneu-monia, with the objective of prioritizing their care to achieve management goals as quickly as possible and reduce the mortality of these patients.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Young Adult , Pneumonia , Pneumonia, Pneumococcal , Pneumonia, Mycoplasma , Pneumonia, Staphylococcal , Pneumonia, Bacterial , Chlamydial Pneumonia , Respiratory Distress Syndrome, Newborn , Shock, Septic , Pulmonary Disease, Chronic Obstructive , Infections , Intensive Care Units
14.
Cambios rev. méd ; 20(1): 74-79, 30 junio 2021.
Article in Spanish | LILACS | ID: biblio-1292925

ABSTRACT

INTRODUCCIÓN. Para el tratamiento farmacoterapéutico de enfermedades respi-ratorias, el uso de herramientas para abordar la vía inhalatoria es de elección por su mayor eficacia y menos efectos secundarios; registrar su adhesión y prevalencia es importante. OBJETIVO. Determinar el nivel y la prevalencia de adhesión al uso de inhaladores en pacientes con Asma y Enfermedad Pulmonar Obstructiva Cróni-ca. MATERIALES Y MÉTODOS. Estudio analítico transversal. Población de 215 y muestra de 121 Historias Clínicas. Se aplicó el Test de Adhesión a Inhaladores, que consistió en dos cuestionarios complementarios: el de 10 ítems, que valoró el nivel de adhesión, y el de 12 que identificó el tipo de incumplimiento en pacientes de Consulta Externa de la Unidad Técnica de Neumología del Hospital de Especialidades Carlos Andrade Marín, periodo julio 2018 - enero 2019. La tabulación y análisis de datos se realizó con el programa Excel. RESULTADOS. La prevalencia de mala adhesión en asmáticos fue de 83,33% y en Enfermedad Pulmonar Obstructiva Crónica 13,33%. En cuanto al sexo, la prevalencia de mala adhesión fue de 15,28% en hombres y de 40,82% en mujeres, con una p<0,05. No se encontró diferencia significativa respecto a los niveles de instrucción. CONCLUSIÓN. La prevalencia de mala adhesión al uso de inhaladores en pacientes con Asma y Enfermedad Pulmonar Obstructiva Crónica fue alta sobre todo en los asmáticos.


INTRODUCTION. For respiratory diseases and their pharmacotherapeutic treatment, the use of tools to address the inhalation route is chosen due to its greater efficacy and fewer secondary effects; then record the adherence and prevalence is important. OBJECTIVE. To determine both level and prevalence of adherence to the use of inhalers in patients with Asthma and Chronic Obstructive Pulmonary Disease. MATE-RIALS AND METHODS. Cross-sectional analytical study. Population of 215 and sam-ple of 121 patients. The Inhaler Adherence Test was applied, which consisted of two complementary questionnaires: a 10-item questionnaire, which assessed the level of adherence, and a 12-item questionnaire that identified the type of non-compliance in patients of the Pneumology Technical Unit of the Hospital de Especialidades Carlos Andrade Marín, period July 2018 - January 2019. The tabulation and data analysis was performed with Microsoft Excel program. RESULTS. The prevalence of poor ad-herence in asthmatics was 83.33% and in Chronic Obstructive Pulmonary Disease was 13.3%. Regarding gender, the prevalence of poor adherence was 15.28% in men and 40.82% in women, with a p <0.05. No significant differences were found regarding the levels of instruction. CONCLUSION. The prevalence of poor adherence to the use of inhalers in patients with Asthma and Chronic Obstructive Pulmonary Disease was high, especially in asthmatics


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Aged , Young Adult , Respiratory Tract Diseases , Asthma , Nebulizers and Vaporizers , Pulmonary Medicine , Pulmonary Disease, Chronic Obstructive , Treatment Adherence and Compliance , Respiratory Therapy , Bronchodilator Agents , Medication Therapy Management , Medication Adherence , Dry Powder Inhalers
15.
Rev. APS ; 23(4): 873-886, 2021-06-23.
Article in Portuguese | LILACS | ID: biblio-1358366

ABSTRACT

As doenças respiratórias crônicas, como a doença pulmonar obstrutiva crônica (DPOC) e a asma, afetam centenas de milhões de pessoas em todo o mundo, sendo a prevalência dessas doenças mais elevada nos países em desenvolvimento. Essas patologias têm consequências significativas em relação à qualidade de vida dos pacientes e a instituição de um tratamento é preponderante para a melhora do estado de saúde. No entanto, a eficácia do tratamento depende não apenas da disponibilidade do medicamento adequado, mas de seu uso correto. A via inalatória é a via de escolha primária para o tratamento da asma e da doença pulmonar obstrutiva crônica, mas os pacientes costumam encontrar dificuldades para usar corretamente os dispositivos inalatórios. Para o desenvolvimento deste trabalho foi realizada revisão integrativa da literatura, com o objetivo de demonstrar a importância da atenção farmacêutica aos pacientes portadores de DPOC e asma. A atenção farmacêutica, que envolve a conduta peculiar do farmacêutico na área de assistência ao paciente, pode prevenir a ocorrência de problemas relacionados ao uso de medicamentos para DPOC e asma, melhorar a adesão à terapêutica medicamentosa e melhorar a qualidade de vida desses pacientes, de seus famílias e pessoas próximas. A atuação do farmacêutico em nível de atenção básica permite que esse profissional acompanhe os pacientes de forma sistematizada, podendo também auxiliar os usuários do sistema de saúde a melhorar o acesso aos medicamentos prescritos e a adotar medidas não farmacológicas, atuando positivamente para uma atenção à saúde de forma equânime e integral.


Chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and asthma, affect hundreds of millions of people worldwide, with the prevalence of these diseases being highest in developing countries. These pathologies have significant consequences in relation to the patients' quality of life and the institution of a treatment is preponderant for the improvement of health status. However, the effectiveness of the treatment depends not only on the availability of the appropriate medication, but on its correct use. The inhalation route is the primary route of choice for the treatment of asthma and chronic obstructive pulmonary disease, but patients often find it difficult to use inhaled devices correctly. For the development of this work, an integrative literature review was carried out, in order to demonstrate the importance of pharmaceutical care to patients with COPD and asthma. Pharmaceutical care, which involves the pharmacist's peculiar conduct in patient care, can prevent the occurrence of problems related to the use of medications for COPD and asthma, improve adherence to drug therapy and improve the quality of life of these patients, their families and close people. The role of the pharmacist at the level of primary care allows this professional to monitor patients in a systematic way, and can also help users of the health system to improve access to prescription drugs and to adopt non-pharmacological measures, acting positively for health care in an equitable and integral way.


Subject(s)
Pharmaceutical Services , Asthma , Pulmonary Disease, Chronic Obstructive
16.
Rev. cuba. med ; 60(2): e1476, tab, graf
Article in Spanish | LILACS, CUMED | ID: biblio-1280343

ABSTRACT

Introducción: La enfermedad pulmonar obstructiva crónica es un problema sanitario mundial por su elevada prevalencia, morbilidad y cuantioso costo económico. Objetivo: Caracterizar mediante la pletismografía a los pacientes con diagnóstico de enfermedad pulmonar obstructiva crónica que presentaron una discrepancia clínica espirométrica. Métodos: Se realizó un estudio descriptivo y transversal en 33 pacientes con diagnóstico de enfermedad pulmonar obstructiva crónica que acudieron a consulta externa del Hospital Neumológico Benéfico Jurídico y el Centro de Investigaciones Clínicas. Se les realizaron volúmenes pulmonares por pletismografía corporal y espirometría en el período comprendido de noviembre 2016 a marzo 2018. Resultados: El sexo masculino (69,7 por ciento) resultó el más frecuente y el grupo de edad predominante fue mayor de 65 años (60,6 por ciento). El 41,2 por ciento de los pacientes presentaron grado de obstrucción moderadamente severo. La capacidad pulmonar total y el volumen residual fueron normales (72,7 por ciento y 42,5 por ciento) respectivamente. El 43,8 por ciento de los pacientes presentaron hiperinsuflación leve. El grado 3 de disnea fue el que predominó en los pacientes. El 12,1 por ciento de los pacientes presentaron aumento del volumen residual dado por atrapamiento aéreo grave con la disminución del volumen espiratorio forzado en el primer segundo. Conclusiones: El comportamiento de los volúmenes pulmonares por pletismografía corporal en la enfermedad pulmonar obstructiva crónica con disociación clínico-espirométrica, evidenció la disminución del volumen espiratorio forzado en el primer segundo y el aumento del volumen residual relacionándose con el grado de disnea(AU)


Introduction: Chronic obstructive pulmonary disease is a global health problem due to its high prevalence, morbidity and high economic cost. Objective: By using plethysmography, to describe patients with diagnosis of chronic obstructive pulmonary disease that had spirometric clinical discrepancy. Methods: A descriptive and cross-sectional study was carried out in 33 patients with diagnosis of chronic obstructive pulmonary disease who attended the outpatient clinic at Benéfico Jurídico Pneumologic Hospital and the Clinical Research Centre. Lung volumes were performed by body plethysmography and spirometry from November 2016 to March 2018. Results: The male sex (69.7 percent) was the most frequent and the predominant age group was older than 65 years (60.6 percent). 41.2 percent of the patients had moderately severe degree of obstruction. Total lung capacity and residual volume were normal, 72.7 percent and 42.5 percent, respectively. 43.8 percent of the patients had mild hyperinflation. Grade 3 dyspnea was the one that predominated in the patients. 12.1 percent of the patients showed increased residual volume due to severe air trapping with decreased forced expiratory volume in the first second. Conclusions: The behavior of lung volumes by body plethysmography in chronic obstructive pulmonary disease with clinical-spirometric dissociation, evidenced decrease in forced expiratory volume in the first second and increased in residual volume related to the degree of dyspnea(AU)


Subject(s)
Humans , Plethysmography, Whole Body/methods , Spirometry/methods , Pulmonary Disease, Chronic Obstructive/epidemiology , Epidemiology, Descriptive , Cross-Sectional Studies
18.
Cuad. Hosp. Clín ; 62(1): 38-45, jun. 2021. ilus.
Article in Spanish | LILACS | ID: biblio-1284260

ABSTRACT

OBJETIVOS: determinar las principales características demográficas, clínicas, radiológicas y de función pulmonar de los pacientes con bronquiectasias en la Clínica del Pulmón. MATERIAL Y MÉTODOS: estudio observacional, retrospectivo. Se revisaron las historias clínicas de 23 pacientes con diagnóstico de dilataciones bronquiales. RESULTADOS: de los 23 pacientes, con una edad media de 49,4 ± 3,87 años, 13 corresponden al sexo femenino y 10 al sexo masculino, el tiempo de evolución de la enfermedad desde el diagnóstico de la patología inicial es de 17,3 ± 2,92 años. La tuberculosis es la etiología principal en 15 pacientes (65,2%). Las manifestaciones clínicas más frecuentes son la tos y expectoración mucopurulenta por varios años en la mayoría de los pacientes, al que añadimos la disnea y hemoptisis, la auscultación pulmonar revela la presencia de crépitos en 17 pacientes (73,9%). La Tomografía de Tórax de Alta Resolución distingue dos tipos de bronquiectasias: La sacular o quística y la cilíndrica, de localización unilobar, bilobar y multilobar (difuso). La Espirometría Forzada fue indicada en 10 pacientes (43,5%) 7 mujeres y 3 varones, el Síndrome Bronquial Obstructivo fue el hallazgo más frecuente. La asociación de Tetraciclina con Metronidazol indicado en 9 pacientes (39,1%) mejoró el cuadro clínico. La fisiopatología de esta entidad clínica está sujeta a una constante actualización. CONCLUSIONES: en pacientes tosedores crónicos, las bronquiectasias deben tener prioridad diagnóstica, se trata de una patología antigua, pero de actualidad permanente.


The purpose of this document is to determine the main epidemiological and clinical characteristics of patients with bronchiectasis at the Lung Clinic. METHOD: observational, retrospective study. The medical records of 23 patients diagnosed with bronchial dilation were reviewed. RESULTS: the results of the 23 patients studied, with a mean age of 49,4 ± 3,87 years, 13 correspond to the female sex and 10 to the male sex, indicate that the time of evolution of the disease from the diagnosis of the initial pathology is: 17,3 ± 2,92 years. Tuberculosis is the main etiology in 15 patients (65,2%). The most frequent clinical manifestations were cough and mucopurulent expectoration of several years in most of the patients, to which we must add dyspnea and hemoptysis, pulmonary auscultation reveals the presence of crepitus in 17 patients (73,9%). High Resolution Chest Tomography distinguishes two types of bronchiectasis: the saccular or cystic and the cylindrical, the localization is unilobar, bilobar and multilobar (diffuse). Forced spirometry was indicated in 10 patients (43,5%), 7 women and 3 men, Chronic Obstructive Pulmonary Disease is the main diagnosis. The association of Tetracycline with Metronidazole indicated in 9 patients (39,1%) had positive results. The pathophysiology of this clinical entity is subject to constant updating. CONCLUSIONS: in chronic coughing patients, bronchiectasis must have diagnostic priority, it is an old pathology, but it is permanently current


Subject(s)
Humans , Male , Female , Middle Aged , Bronchiectasis , Pulmonary Disease, Chronic Obstructive , Auscultation , Spirometry , Tuberculosis , Dyspnea , Hemoptysis , Metronidazole
19.
Int. j. med. surg. sci. (Print) ; 8(2): 1-12, jun. 2021. tab
Article in Spanish | LILACS | ID: biblio-1284425

ABSTRACT

Introducción: La identificación de los fenotipos clínicos son claves en la modulación de la expresión clínica, para un tratamiento integrado de la EPOC. Objetivos: Caracterizar los fenotipos clínicos de la EPOC en los pacientes atendidos en el Hospital Neumológico Benéfico Jurídico. Métodos:Se realizó un estudio observacional descriptivo retrospectivo, en 172 pacientes con diagnóstico de EPOC, en el Hospital Neumológico Benéfico Jurídico durante el año 2017.Resultados: El 38,4 % de los pacientes tenían edad entre 70-79 años. Del total de pacientes, el 54,6 % eran del sexo masculino. El 52,9 % eran fumadores activos y el 41,3 % exfumadores. Aunque las diferencias no fueron significativas, la edad avanzada y el sexo masculino fueron más frecuentes en el fenotipo enfisematoso agudizador y agudizador bronquítico crónico. El tabaquismo activo fue más frecuente en el fenotipo enfisematoso agudizador. Todos los pacientes con el fenotipo agudizador bronquítico crónico tuvieron dos o más exacerbaciones, mientras que el enfisematoso agudizador se relacionó con una severidad grave de la EPOC (46,7 %). Conclusiones: El sexo masculino y la edad avanzada muestran una tendencia a relacionarse con el fenotipo enfisematoso agudizador y agudizador bronquítico crónico, mientras que el tabaquismo activo es más frecuente en el fenotipo enfisematoso agudizador. El fenotipo agudizador bronquítico crónico se relaciona con mayores exacerbaciones y el enfisematoso agudizador con una mayor severidad de la EPOC.


Introduction: The identification of clinical phenotypes are key in the modulation of clinical expression, for an integrated treatment of COPD. Objectives: To characterize the clinical phenotypes of COPD in patients treated at the Hospital Neumológico Benéfico Jurídico. Methods: A retrospective descriptive observational study was carried out in 172 patients with a diagnosis of COPD at the Hospital Neumológico Benéfico Jurídico in 2017. Results: 38.4 % of the patients were between 70-79 years of age. Of the total number of patients, 54.6 % were male. 52.9 % were active smokers and 41.3 % ex-smokers. Although the differences were not significant, advanced age and male sex were more frequent in the exacerbator emphysematous and chronic bronchial exacerbator phenotype. Active smoking was more frequent in the exacerbating emphysematous phenotype. All patients with the chronic bronchial exacerbator phenotype had two or more exacerbations, while exacerbation emphysematous was associated with severe severity of COPD (46.7 %). Conclusions: Male sex and advanced age show a tendency to be related to the exacerbating emphysematous phenotype and chronic bronchitis exacerbator, while active smoking is more frequent in the exacerbating emphysematous phenotype. The chronic bronchitis exacerbator phenotype is related to greater exacerbations and exacerbation emphysematous with a greater severity of COPD


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Aged , Aged, 80 and over , Phenotype , Pulmonary Disease, Chronic Obstructive/genetics , Pulmonary Disease, Chronic Obstructive/epidemiology , Tobacco Use Disorder , Severity of Illness Index , Retrospective Studies , Analysis of Variance , Sex Distribution , Age Distribution , Cuba/epidemiology , Pulmonary Disease, Chronic Obstructive/classification
SELECTION OF CITATIONS
SEARCH DETAIL